KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Issued (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Shares Issued data on record, last reported at $54.0 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 57.43% year-over-year to $54.0 million; the TTM value through Dec 2025 reached $127.7 million, up 11.43%, while the annual FY2025 figure was $127.7 million, 11.43% up from the prior year.
  • Shares Issued reached $54.0 million in Q4 2025 per VRTX's latest filing, up from $7.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $64.4 million in Q2 2022 and bottomed at $7.9 million in Q3 2025.
  • Average Shares Issued over 5 years is $33.3 million, with a median of $34.5 million recorded in 2021.
  • Peak YoY movement for Shares Issued: plummeted 80.4% in 2021, then soared 165.22% in 2022.
  • A 5-year view of Shares Issued shows it stood at $34.7 million in 2021, then soared by 48.7% to $51.6 million in 2022, then dropped by 10.08% to $46.4 million in 2023, then fell by 26.08% to $34.3 million in 2024, then surged by 57.43% to $54.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $54.0 million in Q4 2025, $7.9 million in Q3 2025, and $49.1 million in Q2 2025.